Myeloproliferative Neoplasms News

Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.

AVID200 led to significant reduction in serum transforming growth factor beta levels and improved platelet counts among patients with advanced myelofibrosis, according to study results presented at ASH Annual Meeting and Exposition.

Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit below 45% without phlebotomy, according to a study presented at ASH Annual Meeting and Exposition.

Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19, study results showed.

A vast majority of patients with acute myeloid leukemia and myelodysplastic syndrome converted to seropositivity after two COVID-19 vaccine doses, according to a study presented at ASH Annual Meeting and Exposition.

Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody response, according to results of a prospective, observational single-center study presented at ASH Annual Meeting and Exposition.

The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.

In certain settings.

Sepsis is a leading cause of preventable death across the globe, and patients with cancer have a 10 times higher likelihood of developing this life-threatening condition than those without cancer.

The FDA approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.